Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858338 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
A Phase 2 study of Gastric Cancer and Stomach Cancer, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT00858338: Completed Phase 2 study of Gastric Cancer and Stomach Cancer, sponsored by NYU Langone Health.
NCT00858338 is a Phase 2 study of Gastric Cancer and Stomach Cancer that has completed, run by NYU Langone Health. The registered enrollment target is 28 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00858338, a Phase 2 study of Gastric Cancer and Stomach Cancer, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.
Conditions Studied
Interventions
- PROCEDURE Potentially curative surgery
- DRUG Floxuridine (IP)
- PROCEDURE Adjuvant Chemoradiation therapy
Study Locations (3)
New York
- Bellevue Hospital - New York
- NYU Cancer Center - New York
- NYU Tisch Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-12 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
What the finished NCT00858338 record still lists
NCT00858338 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Potentially curative surgery is the first listed.
NCT00858338 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00858338 about?
NCT00858338 is a clinical study titled "Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer". This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.
What is the current status of trial NCT00858338?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2002-12. Estimated completion is 2012-02.
What conditions does trial NCT00858338 study?
This clinical trial studies the following conditions: Gastric Cancer, Stomach Cancer.
What interventions are being tested in trial NCT00858338?
The interventions under investigation include: Potentially curative surgery (PROCEDURE), Floxuridine (IP) (DRUG), Adjuvant Chemoradiation therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00858338?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00858338 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00858338's enrollment target sits among peer trials
28 140th of 153 higher than 14 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia